Hypofractionated Stereotactic Radiotherapy for Non-breast or Prostate Cancer Oligometastases: A Tail of Survival Beyond 10 Years

Overview of attention for article published in Frontiers in oncology, February 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

policy: 1 policy source

twitter: 2 X users

Readers on

mendeley: 27 Mendeley

Summary Policy documents X

So far, Altmetric has seen 1 policy document that references this research output.

Stereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer

Cited by Canadian Agency for Drugs and Technologies in Health on 20 Jun 2022

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.